Anodyne Therapy reimbursement support
This article was originally published in The Gray Sheet
Executive Summary
More than 1,000 patients and physical therapists submitted comments to CMS in support of national coverage for the Anodyne Therapy infrared device to treat peripheral neuropathy during the comment period ended Feb. 26. Anodyne contacted customers to encourage them to voice their support, a strategy that it has successfully used to reverse previous local coverage denials. In the internally generated national coverage request, CMS cites concerns from an FDA warning letter to the manufacturer as an impetus for considering national non-coverage of the device (1"The Gray Sheet" Feb. 6, 2006, p. 5). CMS plans to issue a proposed decision by July 26...